Proteins represent 95% of drug targets designed to combat disease, according to Yvonne Tan, PhD, from Nuclera.

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Using neem tree extracts as a starting point, scientists have created several kinds of nanozymes and tested them for ...

Early research shows that editing expanding trinucleotide repeats halts the lengthening process that causes neurological ...

Study suggests gasdermin D inhibition may protect mice by blocking release of cellular contents into the extracellular environment.

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

A scientist says he has shown that it’s possible to produce a large amount of virus-like particles using a fully scalable process.

Single-use continuous bioprocessing can reduce mAb production costs and shorten time-to-market compared to batch processing.

Wacker and Expression Manufacturing want to offer clients with an end-to-end, optimized solution for viral vector development and production.

The first systematic genome-wide association study for pseudogout has identified two genes strongly associated with disease progression.

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after infection clears.